Should You Buy KPJ Healthcare Berhad (KLSE:KPJ) For Its Upcoming Dividend?
Readers hoping to buy KPJ Healthcare Berhad (KLSE:KPJ) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. Typically, the ex-dividend date is two business days before the record date, which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is important as the process of settlement involves at least two full business days. So if you miss that date, you would not show up on the company's books on the record date. Accordingly, KPJ Healthcare Berhad investors that purchase the stock on or after the 19th of June will not receive the dividend, which will be paid on the 11th of July.
The company's next dividend payment will be RM00.008 per share, and in the last 12 months, the company paid a total of RM0.041 per share. Looking at the last 12 months of distributions, KPJ Healthcare Berhad has a trailing yield of approximately 1.5% on its current stock price of RM02.79. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. As a result, readers should always check whether KPJ Healthcare Berhad has been able to grow its dividends, or if the dividend might be cut.
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. KPJ Healthcare Berhad is paying out an acceptable 54% of its profit, a common payout level among most companies. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. It distributed 36% of its free cash flow as dividends, a comfortable payout level for most companies.
It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.
View our latest analysis for KPJ Healthcare Berhad
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. With that in mind, we're encouraged by the steady growth at KPJ Healthcare Berhad, with earnings per share up 9.3% on average over the last five years. Decent historical earnings per share growth suggests KPJ Healthcare Berhad has been effectively growing value for shareholders. However, it's now paying out more than half its earnings as dividends. Therefore it's unlikely that the company will be able to reinvest heavily in its business, which could presage slower growth in the future.
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. In the past 10 years, KPJ Healthcare Berhad has increased its dividend at approximately 11% a year on average. It's encouraging to see the company lifting dividends while earnings are growing, suggesting at least some corporate interest in rewarding shareholders.
Has KPJ Healthcare Berhad got what it takes to maintain its dividend payments? Earnings per share growth has been modest and KPJ Healthcare Berhad paid out over half of its profits and less than half of its free cash flow, although both payout ratios are within normal limits. All things considered, we are not particularly enthused about KPJ Healthcare Berhad from a dividend perspective.
Wondering what the future holds for KPJ Healthcare Berhad? See what the 16 analysts we track are forecasting, with this visualisation of its historical and future estimated earnings and cash flow
If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Morgan Stanley Sees 8.8% EPS CAGR for Centene (NYSE:CNC), Initiates Coverage with $70 target.
Centene Corporation (NYSE:CNC) is one of the 8 cheap beginner stocks to buy right now. On June 9, Morgan Stanley analysts began covering Centene Corporation (NYSE:CNC) with an Overweight rating and a $70 price target. The analysts emphasized Centene's status as a prominent managed care provider, particularly within the Medicare Advantage, Medicaid, and Individual Exchange programs. Centene's robust footprint in the Medicaid market is a significant asset, the analysts pointed out, despite the program's difficulties, which include financing instability and state rate-member acuity mismatch. In order to support long-term growth, they also highlighted possible expansion prospects in the ICHRA market and D-SNP integration. Morgan Stanley also highlighted the possibility of ongoing cost reductions along with faster growth in better margin categories, which might eventually result in margin increase. The firm predicts that over the next three years, these elements combined with capital deployment will sustain an EPS compound annual growth rate of 8.8%. Centene Corporation (NYSE:CNC), headquartered in St. Louis, Missouri, is a managed care company that serves as a middleman between government-sponsored and privately insured healthcare programs. While we acknowledge the potential of CNC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
33 minutes ago
- Yahoo
Gates Industrial (GTES) Gets Target Hike as Margin Expansion Confidence Grows
Gates Industrial Chemical Corporation (NYSE:GTES) is one of the 8 cheap beginner stocks to buy right now. Jeffrey Hammond, a KeyBanc analyst, raised his price target for Gates Industrial Chemical Corporation (NYSE:GTES) from $23 to $26 on June 9 while maintaining the stock's rating of Overweight. This decision comes after meetings with investors and meetings with Ivo Jurek, the company's CEO. Gates Industrial is effectively controlling manageable elements to boost earnings without depending on higher volume, even as demand trends are erratic. By innovating and gaining market share, the company is also appears to be growing in its markets. Even in the absence of a notable end-market rebound, Hammond stated he is now more confident that Gates Industrial Chemical Corporation (NYSE:GTES) will be able to meet its margin targets by the end of 2026. This confidence is a result of the company's proven ability to improve profit margins and penetrate more markets. Gates Industrial Chemical Corporation (NYSE:GTES) is a multinational producer of fluid power and power transmission solutions. The company supplies products to original equipment manufacturers (OEMs) as well as replacement channel clients in a variety of industrial and consumer markets. While we acknowledge the potential of GTES as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
39 minutes ago
- Yahoo
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the first child in its Phase 2 clinical trials called INTEGUMENT-INFANT. The trial aims to test the safety and tolerability of an investigational topical treatment, ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. There are currently very few approved topical or systemic therapies for infants with atopic dermatitis. Atopic dermatitis lifelong chronic condition in children that can impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers, said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). A biotechnologist working in a laboratory, examining the effects of a Janus Kinase type 1 inhibitor on plaque psoriasis. This INTEGUMENT-INFANT trial builds on previous positive results from the MUSE study, which also evaluated roflumilast cream 0.05% in infants with atopic dermatitis. ZORYVE cream contains roflumilast, a highly potent and selective phosphodiesterase-4 inhibitor designed for topical use. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage dermatology company focused on developing innovative treatments for immune-mediated skin diseases. It develops targeted topical therapies for major inflammatory skin conditions such as atopic dermatitis and alopecia areata. While we acknowledge the potential of ARQT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data